C91.10 Chronic lymphocytic leukemia of B-cell type not having achieved remission

Name of the Condition

• Chronic lymphocytic leukemia of B-cell type not having achieved remission
• ICD-10 Code: C91.10

Summary

Chronic lymphocytic leukemia of B-cell type not having achieved remission (C91.10) is a subtype of chronic lymphocytic leukemia (CLL) where the disease persists despite treatment and has not responded to therapy. It involves the accumulation of abnormal B lymphocytes in the blood, bone marrow, and lymphoid tissues, with ongoing disease activity. This condition is characterized by a lack of remission, meaning the cancer remains detectable and may continue to progress or cause symptoms.

Causes

The exact cause of CLL, including cases where remission is not achieved, is not fully understood. It involves genetic mutations in B lymphocytes that disrupt normal cell regulation, leading to uncontrolled proliferation. Contributing factors may include environmental exposures, genetic predispositions, and alterations in immune system function. The failure to achieve remission may relate to inherent disease biology, treatment resistance, or incomplete response to therapy.

Risk Factors

• Increasing age (most common in adults over 60)
• Family history of CLL or other lymphoid cancers
• Certain genetic conditions (e.g., inherited immune disorders)
• Prior exposure to certain chemicals or radiation (less clearly established)
• Resistance to standard treatments

Symptoms

• Persistent fatigue and weakness
• Swollen lymph nodes (especially in the neck, armpits, or groin)
• Enlarged spleen or liver
• Frequent infections due to impaired immune function
• Unexplained weight loss
• Night sweats or fever

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess cell counts and identify abnormal lymphocytes. A bone marrow biopsy is typically performed to confirm the presence of CLL and evaluate disease activity. Imaging studies (e.g., CT scans) may assess lymph node or organ involvement. Persistent disease activity, despite treatment, confirms the diagnosis of C91.10.

Treatment Options

Treatment focuses on managing symptoms and controlling disease progression. Options may include targeted therapies (e.g., BTK inhibitors, BCL-2 inhibitors), immunotherapy, or chemotherapy. Clinical trials may be considered for refractory cases. Supportive care, such as infection prevention or transfusions, addresses complications.

Prognosis and Follow-Up

Prognosis varies based on disease biology and response to therapy. Regular follow-up with blood tests, imaging, and clinical assessments monitors disease activity. Long-term management aims to control symptoms and delay progression, though cure is unlikely in this setting.

Complications

• Increased risk of infections due to impaired immunity
• Autoimmune disorders (e.g., hemolytic anemia)
• Transformation to a more aggressive lymphoma (Richter's transformation)
• Organ dysfunction from lymphoid infiltration (e.g., spleen or liver enlargement)

Lifestyle & Prevention

• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Avoid exposure to known carcinogens (e.g., tobacco, certain chemicals)
• Stay up-to-date with vaccinations (as recommended by a healthcare provider)
• Manage stress through relaxation techniques or support groups

When to Seek Professional Help

Seek medical attention if symptoms worsen, such as increased fatigue, new or worsening infections, unexplained weight loss, or persistent fever. Prompt evaluation is important for adjusting treatment or addressing complications.

Tips for Medical Coders

Document the lack of remission clearly in the medical record, including treatment history and evidence of persistent disease (e.g., lab results, imaging). Ensure the code C91.10 is used only when remission has not been achieved after appropriate therapy. Differentiate from other CLL subtypes or remission statuses based on clinical documentation.